

Paul H Naylor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11646683/publications.pdf>

Version: 2024-02-01

47
papers

747
citations

567281

15
h-index

580821

25
g-index

48
all docs

48
docs citations

48
times ranked

367
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance characteristics of EUS-FNA biopsy for adrenal lesions: A meta-analysis. <i>Endoscopic Ultrasound</i> , 2019, 8, 180.	1.5	11
2	Variations in Screening Adenoma Detection Rate by Specialty of Physicians in a Predominately African American Population. <i>Cureus</i> , 2019, 11, e6003.	0.5	2
3	Overlapping molecular signaling of IRX-2 and Ta1 resulting in synergistic biological activity. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 85-88.	3.1	0
4	Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 13-16.	2.5	3
5	Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 291-301.	1.2	10
6	Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 771-782.	4.2	39
7	A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 783-788.	4.2	11
8	Peptide Based Vaccine Approaches for Cancer’A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. <i>Cancers</i> , 2011, 3, 3991-4009.	3.7	12
9	Preclinical studies with IRX and thymosin in combination therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 162-168.	3.8	4
10	IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. <i>Vaccine</i> , 2010, 28, 7054-7062.	3.8	12
11	Immunopharmacology of Thymosin and Cytokine Synergy. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 235-244.	3.8	16
12	T cell targeted immune enhancement yields effective T cell adjuvants. <i>International Immunopharmacology</i> , 2003, 3, 1205-1215.	3.8	19
13	Effect of Peptide-Carrier Coupling on Peptide-Specific Immune Responses. <i>Immunobiology</i> , 2001, 203, 601-615.	1.9	15
14	Zadaxin (thymosin) for the treatment of viral hepatitis. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 281-287.	4.1	5
15	CYTOKINE-MEDIATED APOPTOSIS AND INHIBITION OF VIRUS PRODUCTION AND ANCHORAGE INDEPENDENT GROWTH OF VIRAL TRANSFECTED HEPATOBLASTOMA CELLS. <i>Cytokine</i> , 1998, 10, 586-595.	3.2	11
16	Thymosin-, but not interferon-, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. <i>Journal of Hepatology</i> , 1996, 25, 814-820.	3.7	12
17	Thymus-Derived Peptides in the Treatment of Viral Chronic Hepatitis. <i>Digestive Diseases</i> , 1996, 14, 362-370.	1.9	10
18	Thymosin does not promote growth or oncogenic transformation. <i>International Journal of Immunopharmacology</i> , 1996, 18, 321-327.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Thymosin $\hat{2}4$ synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. <i>Immunopharmacology</i> , 1993, 26, 83-92.	2.0	11
20	Serum cross-reactive thymosin $\alpha 1$ levels in rats during induction of mammary carcinoma with 7,12-dimethylbenz[a]anthracene: short- and long-term effects. <i>Cancer Letters</i> , 1993, 69, 187-189.	7.2	0
21	Identification of immunoreactive forms of thymosin $\hat{1}1$ in serum and supernatants by combining HPLC and RIA. <i>International Journal of Immunopharmacology</i> , 1992, 14, 1267-1278.	1.1	8
22	Low Thymosin Alpha-1 Concentrations in Patients Chronically Infected with the Hepatitis B Virus*. <i>Viral Immunology</i> , 1991, 4, 195-199.	1.3	23
23	Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine " HGP-30-KLH. <i>International Journal of Immunopharmacology</i> , 1991, 13, 117-127.	1.1	28
24	Changes in circulating levels of neuroendocrine and thymic hormones during aging in rats: A correlation study. <i>Experimental Gerontology</i> , 1990, 25, 149-157.	2.8	12
25	Immune response and epitope mapping of a candidate hiv-1 p17 vaccine hgp30. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 43-47.	2.1	31
26	Diagnostic Assays for Human Immunodeficiency Virus Infection and for Clinical Progression by Use of Synthetic p17 Peptide Epitopes. <i>Monographs in Virology</i> , 1990, 18, 74-90.	0.6	0
27	Diminished thymosin $\alpha 1$ levels in persons exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1989, 28, 285-295.	2.3	16
28	Improved ELISA to measure thymosin $\hat{1}1$: Comparison of whole and absorbed antisera. <i>International Journal of Immunopharmacology</i> , 1988, 10, 795-801.	1.1	13
29	Identification and distribution of thymosin alpha 1-like immunoreactivity. <i>Developmental and Comparative Immunology</i> , 1988, 12, 397-402.	2.3	5
30	Localization of Thymosin $\hat{1}1$ Production to Thymus Medullary Epithelial Cells by Use of Monoclonal Antibodies. <i>Hybridoma</i> , 1987, 6, 47-59.	0.6	10
31	Thymic Physiology and Biochemistry. <i>Advances in Clinical Chemistry</i> , 1987, 26, 203-292.	3.7	24
32	Circulating thymulin and thymosin- $\hat{1}1$ activity in pediatric acquired immune deficiency syndrome: In vivo and in vitro studies. <i>Journal of Pediatrics</i> , 1986, 109, 422-427.	1.8	23
33	Thymosin $\hat{1}1$ and thymosin $\hat{2}4$ in serum: Comparison of normal, cord, homosexual and AIDS serum. <i>International Journal of Immunopharmacology</i> , 1986, 8, 667-676.	1.1	50
34	Thymosins and anti-thymosins: Properties and clinical applications. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1986, 3, 211-21.	1.1	15
35	MicroELISA method for measurement of human serum thymosin $\hat{1}1$. <i>Journal of Immunological Methods</i> , 1985, 80, 45-53.	1.4	19
36	Thymosin in the Staging and Treatment of HLTV-III Positive Homosexuals and Hemophiliacs with AIDS-Related Immune Dysfunction. <i>Advances in Experimental Medicine and Biology</i> , 1985, 187, 129-140.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Immunochemical studies on thymosin: Radioimmunoassay of thymosin $\hat{1}^{24}$. Immunopharmacology, 1984, 7, 9-16.	2.0	55
38	Inverse correlation between age related abnormalities of Tâ€cell immunity and circulating thymosin $\hat{1}\pm₁$ levels in haemophilia A. British Journal of Haematology, 1984, 58, 325-336.	2.5	13
39	The thymus AIDS connection: Thymosin in the diagnosis and treatment of individuals at risk for AIDS. BioEssays, 1984, 1, 63-69.	2.5	8
40	THYMOSIN IN THE EARLY DIAGNOSIS AND TREATMENT OF HIGH RISK HOMOSEXUALS AND HEMOPHILIACS WITH AIDS-LIKE IMMUNE DYSFUNCTION. Annals of the New York Academy of Sciences, 1984, 437, 88-97.	3.8	20
41	Isolation of thymosin $\hat{1}\pm 1$ from thymosin fraction 5 of different species by high-performance liquid chromatography. Journal of Chromatography A, 1983, 266, 533-544.	3.7	33
42	Abnormally elevated thymosin $\hat{1}\pm 1$ levels in the acquired immunodeficiency syndrome (AIDS). Clinical Immunology Newsletter, 1983, 4, 126-128.	0.1	3
43	Cyclic nucleotide changes in murine lymphocytes following thymosin incubation in vitro. Immunopharmacology, 1979, 1, 89-101.	2.0	10
44	Effect of calcium on the cyclic GMP elevation induced by thymosin fraction 5. Biochemical and Biophysical Research Communications, 1979, 90, 810-818.	2.1	19
45	Thymosin: Cyclic nucleotides and T cell differentiation. Life Sciences, 1979, 25, 301-309.	4.3	22
46	Effect of thymosin and lipopolysaccharide on murine lymphocyte cyclic AMP. Journal of Immunological Methods, 1978, 20, 143-153.	1.4	15
47	Increase of cyclic GMP induced in murine thymocytes by thymosin fraction 5. Biochemical and Biophysical Research Communications, 1976, 73, 843-849.	2.1	58